> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Anson Reports 6.6% Silo Pharma Stake Through Private Funds It Co-Advises
- URL: https://www.bullished.co/anson-reports-6-6-silo-pharma-stake-through-private-funds-it-co-advises-44b871ef/
- Published: 2026-11-16T15:56:47.000Z
- Updated: 2026-11-16T15:56:47.000Z
- Description: The investment adviser shares voting authority over 103,983 shares held by private funds.
- Author: Matteo Parrino
- Tags: SEC Filings, SILO, Industry: Healthcare, Topic: Ownership & Activism

Anson Funds Management LP, an investment adviser, reported a [6.6% stake](https://www.sec.gov/Archives/edgar/data/0001491072/000119312526462547/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in Silo Pharma, which develops conventional and psychedelic-based drug candidates and holds cryptocurrencies. The passive ownership filing submitted Monday covered 103,983 common shares held by private funds it jointly advises, with the position measured as of September 30, 2026.

## Shared Authority Over The Funds' Shares

Anson Funds Management LP and Anson Advisors co-advise the private funds that own the stock. Both advisers can direct how those shares are voted and sold; Anson Funds Management LP reported shared voting power over the entire position and zero shares under its sole voting authority.

The same position is attributed to Anson Management GP, the manager's general partner, and Tony Moore, principal of the manager and general partner. Amin Nathoo and Moez Kassam, directors of Anson Advisors, can each direct the funds' votes and share dispositions.

The reporting parties certified that the funds bought and hold the stock as part of their ordinary business activities, without seeking to change or influence Silo's control.

## The Share Count Behind 6.6%

The percentage uses [1,588,250 outstanding shares](https://www.sec.gov/Archives/edgar/data/0001491072/000119312526462547/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co), the common-stock count Silo reported in its quarterly report filed August 13, 2026\. Anson used that count as the base for the funds' 103,983-share position.

Silo Pharma shares tumbled about 6% to $1.73 in Monday trading. Its market value was $4 million as of Monday's original report.

## Drug Programs And Digital Assets

Silo's four drug programs address post-traumatic stress disorder and anxiety, fibromyalgia and chronic pain, Alzheimer's disease, and multiple sclerosis. Its lead candidate, SPC-15, is administered through the nose; SP-26 is a ketamine implant designed to release the drug over time.

Customer license fees provide revenue, with a single licensee supplying 100% of those fees in both 2025 and 2024\. Silo also stakes digital assets to receive cryptocurrency rewards. Its crypto holdings had a fair value of about $221,817 as of December 31, 2025.

Learn

- [13D Filing Requirements And Deadline, Shown With Real Filings →](https://www.bullished.co/learn/13d-filing-requirements/)  
A Schedule 13D is required when you own more than 5% of a public company's voting shares. See the deadline, contents and real filings from this week.
- [13D Vs 13G: What Each 5% Stake Filing Means And How To Read One →](https://www.bullished.co/learn/13d-vs-13g/)  
13D vs 13G: both report stakes above 5%, but 13G is the short passive form and 13D explains intent. See real BlackRock and Pictet filings read in plain English.

### Sources

- [SCHEDULE 13G — Anson Funds Management LP re: Silo Pharma, Inc. (SILO)](https://www.sec.gov/Archives/edgar/data/0001491072/000119312526462547/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR